Health Systems and Reform Journal
@hsrjournal.bsky.social
First journal dedicated to research, theory, and analysis in #healthsystems and #healthreform🌍 ┃Publisher: @tandfresearch.bsky.social
https://www.tandfonline.com/toc/khsr20/current
https://www.tandfonline.com/toc/khsr20/current
This indicates that targeted eligibility criteria can support more equitable access within a universal system.
Read more: bit.ly/3MCXX61
Read more: bit.ly/3MCXX61
December 18, 2025 at 2:34 PM
This indicates that targeted eligibility criteria can support more equitable access within a universal system.
Read more: bit.ly/3MCXX61
Read more: bit.ly/3MCXX61
As a result, Māori and Pacific ethnicity was explicitly included as an eligibility criterion for access to these publicly funded medicines.
Early prescribing data suggest improved access for Māori and Pacific peoples compared with other diabetes medicines without eligibility restrictions👇
Early prescribing data suggest improved access for Māori and Pacific peoples compared with other diabetes medicines without eligibility restrictions👇
December 18, 2025 at 2:34 PM
As a result, Māori and Pacific ethnicity was explicitly included as an eligibility criterion for access to these publicly funded medicines.
Early prescribing data suggest improved access for Māori and Pacific peoples compared with other diabetes medicines without eligibility restrictions👇
Early prescribing data suggest improved access for Māori and Pacific peoples compared with other diabetes medicines without eligibility restrictions👇
Initial funding proposals relied on clinical thresholds, testing requirements, and prior treatment history.
Indigenous health experts raised concerns that these criteria would disadvantage Māori and Pacific patients, given known inequities in access to testing, primary care, and earlier treatment👇
Indigenous health experts raised concerns that these criteria would disadvantage Māori and Pacific patients, given known inequities in access to testing, primary care, and earlier treatment👇
December 18, 2025 at 2:34 PM
Initial funding proposals relied on clinical thresholds, testing requirements, and prior treatment history.
Indigenous health experts raised concerns that these criteria would disadvantage Māori and Pacific patients, given known inequities in access to testing, primary care, and earlier treatment👇
Indigenous health experts raised concerns that these criteria would disadvantage Māori and Pacific patients, given known inequities in access to testing, primary care, and earlier treatment👇
The policy focused on access to two newer type 2 diabetes treatments: SGLT-2 inhibitors and GLP-1 receptor agonists, medicines shown to reduce cardiovascular, renal, and mortality risks.
Despite universal coverage, Māori and Pacific peoples historically had lower access to such treatments👇
Despite universal coverage, Māori and Pacific peoples historically had lower access to such treatments👇
December 18, 2025 at 2:34 PM
The policy focused on access to two newer type 2 diabetes treatments: SGLT-2 inhibitors and GLP-1 receptor agonists, medicines shown to reduce cardiovascular, renal, and mortality risks.
Despite universal coverage, Māori and Pacific peoples historically had lower access to such treatments👇
Despite universal coverage, Māori and Pacific peoples historically had lower access to such treatments👇
Despite these limitations, the authors find that HTA is positioned to support wider policy applications across China’s health sector, provided that data systems, governance, and stakeholder participation continue to improve.
Read more: bit.ly/3KA0MUU
Read more: bit.ly/3KA0MUU
December 10, 2025 at 10:48 AM
Despite these limitations, the authors find that HTA is positioned to support wider policy applications across China’s health sector, provided that data systems, governance, and stakeholder participation continue to improve.
Read more: bit.ly/3KA0MUU
Read more: bit.ly/3KA0MUU
Important constraints remain, including limited context relevant data, fragmented governance, minimal patient engagement, and the absence of an independent national HTA authority👇
December 10, 2025 at 10:48 AM
Important constraints remain, including limited context relevant data, fragmented governance, minimal patient engagement, and the absence of an independent national HTA authority👇
This approach has strengthened how China evaluates new technologies and helped align coverage decisions with evidence of value👇
December 10, 2025 at 10:48 AM
This approach has strengthened how China evaluates new technologies and helped align coverage decisions with evidence of value👇
HTA now informs annual decisions on the National Reimbursement Drug List. Expert panels assess medicines across safety, efficacy, economic value, innovation, and equity to guide reimbursement and pricing👇
December 10, 2025 at 10:48 AM
HTA now informs annual decisions on the National Reimbursement Drug List. Expert panels assess medicines across safety, efficacy, economic value, innovation, and equity to guide reimbursement and pricing👇
HTA began as academic work in the 1990s but gradually became an applied policy tool. Over time, China built institutional capacity through dedicated research units and later the National Healthcare Security Administration👇
December 10, 2025 at 10:48 AM
HTA began as academic work in the 1990s but gradually became an applied policy tool. Over time, China built institutional capacity through dedicated research units and later the National Healthcare Security Administration👇
➡️2012: Political debates about how to embrace expensive but important health technologies that were not on the benefits list led to the creation of the Participatory Priority Setting Committee.
Read more: bit.ly/3x0g3rf
Read more: bit.ly/3x0g3rf
December 1, 2025 at 10:37 AM
➡️2012: Political debates about how to embrace expensive but important health technologies that were not on the benefits list led to the creation of the Participatory Priority Setting Committee.
Read more: bit.ly/3x0g3rf
Read more: bit.ly/3x0g3rf
➡️2008: The global UHC movement inspired the domestic movement for expanding the benefit coverage, which in turn led to the launch of the National Evidence-based Healthcare Collaborating Agency (NECA), specializing in HTA research👇
December 1, 2025 at 10:37 AM
➡️2008: The global UHC movement inspired the domestic movement for expanding the benefit coverage, which in turn led to the launch of the National Evidence-based Healthcare Collaborating Agency (NECA), specializing in HTA research👇
➡️2007: The Evidence-based Medicine Team was established at the Center for New HTA, which was nested in the Health Insurance Review and Assessment Service (HIRA). This marked the beginning of the division in decision-making tracks for new drugs and health technologies👇
December 1, 2025 at 10:37 AM
➡️2007: The Evidence-based Medicine Team was established at the Center for New HTA, which was nested in the Health Insurance Review and Assessment Service (HIRA). This marked the beginning of the division in decision-making tracks for new drugs and health technologies👇
➡️The scope of HTA studies should expand beyond solely generating evidence for technologies within the JKN benefits package. It should also encompass public health measures for disease prevention and innovative health technologies
Read more: bit.ly/4g1s7Kq
Read more: bit.ly/4g1s7Kq
November 24, 2025 at 5:04 PM
➡️The scope of HTA studies should expand beyond solely generating evidence for technologies within the JKN benefits package. It should also encompass public health measures for disease prevention and innovative health technologies
Read more: bit.ly/4g1s7Kq
Read more: bit.ly/4g1s7Kq
Future directions for HTA in Indonesia
➡️The HTA body should have a direct regulatory role established by law, with clear links defined between HTA recommendations and decision making
➡️Continue capacity building, academic research and the production of public goods 👇
➡️The HTA body should have a direct regulatory role established by law, with clear links defined between HTA recommendations and decision making
➡️Continue capacity building, academic research and the production of public goods 👇
November 24, 2025 at 5:04 PM
Future directions for HTA in Indonesia
➡️The HTA body should have a direct regulatory role established by law, with clear links defined between HTA recommendations and decision making
➡️Continue capacity building, academic research and the production of public goods 👇
➡️The HTA body should have a direct regulatory role established by law, with clear links defined between HTA recommendations and decision making
➡️Continue capacity building, academic research and the production of public goods 👇
Challenges for the establishment of an HTA ecosystem in Indonesia
➡️Lack of HTA infrastructure
➡️Inadequate funding and limited technical capacity
➡️Inadequate involvement of stakeholders in the HTA process
➡️HTA agency’s lack of autonomy
➡️Lack of HTA infrastructure
➡️Inadequate funding and limited technical capacity
➡️Inadequate involvement of stakeholders in the HTA process
➡️HTA agency’s lack of autonomy
November 24, 2025 at 5:04 PM
Challenges for the establishment of an HTA ecosystem in Indonesia
➡️Lack of HTA infrastructure
➡️Inadequate funding and limited technical capacity
➡️Inadequate involvement of stakeholders in the HTA process
➡️HTA agency’s lack of autonomy
➡️Lack of HTA infrastructure
➡️Inadequate funding and limited technical capacity
➡️Inadequate involvement of stakeholders in the HTA process
➡️HTA agency’s lack of autonomy
Five things HITAP will initiate in the future
1️⃣Developing and updating public goods for HTA
2️⃣Exploring and expanding the frontiers of HTA
3️⃣Balancing efficiency and equity in health
4️⃣Supporting HTA Capacity Building in #LMICs
5️⃣Educating the public
Read more: bit.ly/4c6p5l8
1️⃣Developing and updating public goods for HTA
2️⃣Exploring and expanding the frontiers of HTA
3️⃣Balancing efficiency and equity in health
4️⃣Supporting HTA Capacity Building in #LMICs
5️⃣Educating the public
Read more: bit.ly/4c6p5l8
November 17, 2025 at 8:30 PM
Five things HITAP will initiate in the future
1️⃣Developing and updating public goods for HTA
2️⃣Exploring and expanding the frontiers of HTA
3️⃣Balancing efficiency and equity in health
4️⃣Supporting HTA Capacity Building in #LMICs
5️⃣Educating the public
Read more: bit.ly/4c6p5l8
1️⃣Developing and updating public goods for HTA
2️⃣Exploring and expanding the frontiers of HTA
3️⃣Balancing efficiency and equity in health
4️⃣Supporting HTA Capacity Building in #LMICs
5️⃣Educating the public
Read more: bit.ly/4c6p5l8
Five things HITAP is addressing
1️⃣Evaluating public health interventions
2️⃣Conducting HTA throughout the lifecycle of health technologies
3️⃣Demonstrating HTA impact
4️⃣Stakeholder engagement
5️⃣Being more strategic about human resource planning and management
1️⃣Evaluating public health interventions
2️⃣Conducting HTA throughout the lifecycle of health technologies
3️⃣Demonstrating HTA impact
4️⃣Stakeholder engagement
5️⃣Being more strategic about human resource planning and management
November 17, 2025 at 8:30 PM
Five things HITAP is addressing
1️⃣Evaluating public health interventions
2️⃣Conducting HTA throughout the lifecycle of health technologies
3️⃣Demonstrating HTA impact
4️⃣Stakeholder engagement
5️⃣Being more strategic about human resource planning and management
1️⃣Evaluating public health interventions
2️⃣Conducting HTA throughout the lifecycle of health technologies
3️⃣Demonstrating HTA impact
4️⃣Stakeholder engagement
5️⃣Being more strategic about human resource planning and management
Five things that HITAP did well
1️⃣Building HTA capacity
2️⃣Linking HTA research to policy
3️⃣Mobilizing global support
4️⃣Producing global public goods
5️⃣Having a semi-autonomous status
1️⃣Building HTA capacity
2️⃣Linking HTA research to policy
3️⃣Mobilizing global support
4️⃣Producing global public goods
5️⃣Having a semi-autonomous status
November 17, 2025 at 8:30 PM
Five things that HITAP did well
1️⃣Building HTA capacity
2️⃣Linking HTA research to policy
3️⃣Mobilizing global support
4️⃣Producing global public goods
5️⃣Having a semi-autonomous status
1️⃣Building HTA capacity
2️⃣Linking HTA research to policy
3️⃣Mobilizing global support
4️⃣Producing global public goods
5️⃣Having a semi-autonomous status
➡️Rejecting Inclusion Requests Based on HTA Evidence
The inclusion of ribociclib and palbociclib in the health benefits package was denied because the cost-effectiveness analysis revealed their inclusion remains cost-ineffective in India even with a 95% price reduction.
Read more: bit.ly/3wtaT6Y
The inclusion of ribociclib and palbociclib in the health benefits package was denied because the cost-effectiveness analysis revealed their inclusion remains cost-ineffective in India even with a 95% price reduction.
Read more: bit.ly/3wtaT6Y
November 13, 2025 at 8:55 AM
➡️Rejecting Inclusion Requests Based on HTA Evidence
The inclusion of ribociclib and palbociclib in the health benefits package was denied because the cost-effectiveness analysis revealed their inclusion remains cost-ineffective in India even with a 95% price reduction.
Read more: bit.ly/3wtaT6Y
The inclusion of ribociclib and palbociclib in the health benefits package was denied because the cost-effectiveness analysis revealed their inclusion remains cost-ineffective in India even with a 95% price reduction.
Read more: bit.ly/3wtaT6Y
➡️Using HTA evidence for revising standard treatment guidelines
HeFTA evaluated HTA evidence on trastuzumab cycles for breast cancer, finding it cost-effective to raise the PM-JAY cycle cap from four to eight. Accordingly, the STGs were revised👇
HeFTA evaluated HTA evidence on trastuzumab cycles for breast cancer, finding it cost-effective to raise the PM-JAY cycle cap from four to eight. Accordingly, the STGs were revised👇
November 13, 2025 at 8:55 AM
➡️Using HTA evidence for revising standard treatment guidelines
HeFTA evaluated HTA evidence on trastuzumab cycles for breast cancer, finding it cost-effective to raise the PM-JAY cycle cap from four to eight. Accordingly, the STGs were revised👇
HeFTA evaluated HTA evidence on trastuzumab cycles for breast cancer, finding it cost-effective to raise the PM-JAY cycle cap from four to eight. Accordingly, the STGs were revised👇